학술논문
LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
Document Type
Abstract
Author
Source
In Annals of Oncology June 2023 34 Supplement 1:S178-S179
Subject
Language
ISSN
0923-7534